Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-32 (canceled).

33. (new) An isolated monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601.

34. (new) A nucleic acid encoding the monoclonal antibody of claim 33.

35. (new) The monoclonal antibody of claim 33, wherein said monoclonal antibody specifically binds to amino acids 1-42 of the polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601.

36. (new) A pharmaceutical composition comprising a monoclonal antibody according to claim 33 and a pharmaceutically acceptable carrier.

37. (new) The monoclonal antibody of claim 33, wherein said antibody is a chimeric antibody.

38. (new) The monoclonal antibody of claim 33, wherein said antibody is a Fab fragment.

39. (new) The monoclonal antibody of claim 33, wherein said antibody is a Fv fragment.

40. (new) The monoclonal antibody of claim 33, wherein said antibody is a scFv.

41. (new) The monoclonal antibody of claim 33 further comprising a reporter group.

42. (new) The monoclonal antibody of claim 33 further comprising a therapeutic moiety.

43. (new) The monoclonal antibody of claim 42, wherein the therapeutic moiety is a radionuclide.

44. (new) A pharmaceutical composition comprising a monoclonal antibody of claim 43, and a pharmaceutically acceptable carrier.

45. (new) A method for the treatment of a hematological malignancy in a mammalian subject, the method comprising:

administering to the subject an effective amount of a pharmceutical composition comprising an isolated monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601 and a pharmaceutically acceptable carrier.

46. (new) The method of claim 45, wherein the hematological malignancy is associated with overexpression of Ly1448.

47. (new) The method of claim 45, wherein the hematological malignancy is selected from the group consisting of lymphoma, B cell leukemia, multiple myeloma, and combinations thereof.

48. (new) The method of claim 45, wherein the mammalian subject is a human.

49. (new) The method of claim 45, wherein the administration is intravenous.

50. (new) A method for the detection of a hematological malignancy in a patient, said method comprising:

(a) contacting a biological sample from the patient with a monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601, whereby said monoclonal antibody forms a complex with a polypeptide encoded by SEQ ID NO:9601

(b) detecting the amount of said complex, thereby detecting cancer in said patient.

51. (new) The method of claim 50, wherein the hematological malignancy is selected from the group consisting of: lymphoma, B cell leukemia, and multiple myeloma, and combinations thereof.

52. (new) A kit for detecting a hematological malignancy cell, said kit comprising:

a monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601; and

instructions for use.